Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
SwitzerlandIPO:
18 May 2020Website:
http://www.adctherapeutics.comNext earnings report:
13 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 22:46:13 GMTDividend
Analysts recommendations
Institutional Ownership
ADCT Latest News
ADC Therapeutics SA (NYSE:ADCT ) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Marcy Graham - Investor Relations Ameet Mallik - Chief Executive Officer Pepe Carmona - Chief Financial Officer Lindsay Drucker Mann - Global Chief Financial Officer Conference Call Participants Michael Schmidt - Guggenheim Eric Schmidt - Cantor Fitzgerald Kelly Shi - Jefferies Operator Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Third Quarter 2024 Earnings Conference Call. [Operator Instructions] This call is being recorded on Thursday, November 7, 2024.
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.58 per share a year ago.
Here is how ADC Therapeutics SA (ADCT) and Agios Pharmaceuticals (AGIO) have performed compared to their sector so far this year.
Start Time: 08:30 January 1, 0000 9:04 AM ET ADC Therapeutics SA (NYSE:ADCT ) Q2 2024 Earnings Conference Call August 06, 2024, 08:30 AM ET Company Participants Ameet Mallik - CEO Jose Carmona - CFO Marcy Graham - IRO Conference Call Participants Eric Schmidt - Cantor Fitzgerald Kelly Shi - Jefferies Michael Schmidt - Guggenheim Brian Cheng - JPMorgan Operator Welcome to the ADC Therapeutics Second Quarter 2024 Financial Results Conference Call. My name is Didi, and I will be your operator for today's call.
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.58 per share a year ago.
Fundamentally, biotech stocks to buy operate on a clear and unavoidable narrative: wealth means nothing without health. You hear various stories about extremely wealthy tycoons throwing all kinds of money, not just for lifesaving procedures but in more superficial efforts such as maintaining youth and vitality.
ADC Therapeutics SA (NYSE: ADCT) has revealed that Ameet Mallik, the Chief Executive Officer, will be taking part in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024 at 2:00 p.m. ET.
ADC Therapeutics SA (ADCT) reported a quarterly loss of $0.56 per share, which was in line with the Zacks Consensus Estimate. This is an improvement from the loss of $0.74 per share reported in the same quarter last year.
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.30 per share a year ago.
ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 1(current)
What type of business is ADC Therapeutics SA?
ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
What sector is ADC Therapeutics SA in?
ADC Therapeutics SA is in the Healthcare sector
What industry is ADC Therapeutics SA in?
ADC Therapeutics SA is in the Biotechnology industry
What country is ADC Therapeutics SA from?
ADC Therapeutics SA is headquartered in Switzerland
When did ADC Therapeutics SA go public?
ADC Therapeutics SA initial public offering (IPO) was on 18 May 2020
What is ADC Therapeutics SA website?
https://www.adctherapeutics.com
Is ADC Therapeutics SA in the S&P 500?
No, ADC Therapeutics SA is not included in the S&P 500 index
Is ADC Therapeutics SA in the NASDAQ 100?
No, ADC Therapeutics SA is not included in the NASDAQ 100 index
Is ADC Therapeutics SA in the Dow Jones?
No, ADC Therapeutics SA is not included in the Dow Jones index
When was ADC Therapeutics SA the previous earnings report?
No data
When does ADC Therapeutics SA earnings report?
The next expected earnings date for ADC Therapeutics SA is 13 March 2025